Hormone therapy for women is undergoing a meaningful shift, shaped by updated regulatory guidance, rising demand, and a growing expectation that healthcare should be more accessible, personalized, and responsive to the realities of modern life.
For years, treatment decisions around hormone therapy were influenced by broad safety warnings that came out of early interpretations of large-scale studies in the early 2000s. Those warnings created a cautious environment where many women either delayed treatment, struggled silently through symptoms, or avoided hormone therapy entirely despite significant impacts on their quality of life.
That landscape changed in late 2025. The FDA began removing long-standing boxed warnings from many hormone therapy medications, reflecting a more updated understanding of risk. Rather than applying generalized caution, the agency now emphasizes individualized decision-making based on factors like age, timing, symptom severity, and overall health history. This change has had a direct impact across the healthcare landscape.
More women are now actively seeking treatment for symptoms tied to hormonal changes, including hot flashes, night sweats, disrupted sleep, mood instability, fatigue, brain fog, reduced focus, weight fluctuations, and decreased quality of life. At the same time, healthcare systems are adjusting to meet this increased demand, particularly as awareness surrounding menopause and hormone health continues growing nationally.
The shift is not only medical. It is cultural. Conversations surrounding women’s health, menopause, perimenopause, and hormonal wellness have become significantly more visible in recent years. Women are increasingly advocating for themselves, asking more informed questions, and seeking healthcare solutions that feel proactive rather than dismissive. For many patients, the expectation is no longer simply access to care, but access to care that feels timely, individualized, and easier to navigate.
Shayk is part of a growing group of telehealth platforms working to close that gap. The platform focuses specifically on women’s hormone therapy and simplifies access into a more structured process. Patients begin with a short intake, followed by provider review that typically happens within the same or next day. If treatment is appropriate, prescriptions are issued and delivered directly.
Speed is one part of the model, but it is not the defining feature. The more significant shift is how Shayk approaches continuity of care.
Patients are able to message their provider directly and receive responses within a day. Treatment is not treated as a fixed plan but as something that can evolve based on real feedback, symptom changes, and patient experience over time. Adjustments are built into the system rather than requiring new appointments, long waiting times, or disruptions in care.
This reflects a larger evolution happening across healthcare delivery overall. Patients increasingly expect healthcare interactions to function with the same accessibility, communication, and responsiveness they experience in other parts of their lives. Telehealth models that reduce friction while maintaining clinical oversight are becoming more normalized, particularly for ongoing conditions that require long-term management and regular communication.
This approach also aligns with what current clinical guidance suggests. Hormone therapy works best when it is tailored and monitored over time. A static prescription without follow-up often leads to inconsistent results, unnecessary frustration, or patients abandoning treatment altogether. Ongoing communication and adjustment are critical components of successful long-term care.
Another defining aspect of Shayk’s model is its use of FDA-approved medications only. In a rapidly expanding market, where different types of formulations are being used across platforms, this creates a clear standard. It prioritizes consistency, regulatory alignment, and therapies that have undergone established review processes. As hormone therapy becomes more individualized, many healthcare experts still emphasize the importance of maintaining treatment pathways grounded in approved therapies and structured clinical oversight.
Pricing is also structured transparently, with both monthly and longer-term options available. The model reduces uncertainty and allows patients to understand costs before starting treatment, which is increasingly important as consumers become more price-conscious and proactive about managing healthcare expenses.
At the same time, supply challenges remain across the industry. Increased demand following updated FDA guidance has placed pressure on certain medications, particularly estrogen patches. These shortages have highlighted the importance of having multiple treatment pathways, flexible prescribing models, and consistent provider oversight capable of adapting to supply fluctuations when needed.
Shayk addresses this by offering different forms of therapy while maintaining a unified care model designed around continuity and patient communication.
The broader opportunity within this category continues growing. Millions of women experience symptoms tied to hormonal changes every year, yet many still report feeling underserved, dismissed, or unsupported during the process of seeking treatment. As awareness expands and more women become comfortable discussing hormone health openly, demand for accessible, clinically grounded care models is likely to continue accelerating.
Telehealth platforms are increasingly positioned to play an important role in that evolution, particularly for patients seeking convenience, privacy, faster access, and more direct communication with providers.
As awareness continues to grow and barriers to access continue to fall, hormone therapy is becoming a more central part of women’s healthcare.
Platforms that combine accessibility, clinical structure, regulatory alignment, and continuity of care are likely to define the next phase of this category.